Mati Therapeutics, based in Austin, Texas, is pioneering a non-invasive sustained drug delivery platform specifically designed for the treatment of ocular diseases, with a focus on glaucoma. Their flagship product, the Evolute® Punctal Plug Delivery System, is a small, comfortable device that is inserted into the tear duct to automatically deliver medication over an extended period. This innovative approach eliminates the need for patients or caregivers to administer eye drops, addressing a significant challenge in ocular therapy adherence. The company’s founders bring extensive experience from leading positions in major pharmaceutical firms, underscoring their commitment to improving treatment outcomes in ophthalmology.

The Punctal Plug Drug Delivery System (PPDS) is versatile and compatible with various ophthalmic molecules, allowing it to target multiple ocular conditions. Mati Therapeutics has formulated five different ophthalmic compounds, which have progressed through clinical trials for indications such as post-surgical pain, inflammation, and glaucoma. Additionally, the company has conducted proof-of-concept studies and gathered pre-clinical data for treatments related to dry eye. With a robust patent portfolio and ongoing clinical trials, Mati Therapeutics is positioned to make significant advancements in the field of ocular drug delivery, potentially transforming how ocular diseases are managed.

Canada

Mati Therapeutics is a healthcare company that specializes in developing a proprietary ophthalmic drug delivery system using punctal plugs for introducing therapeutic agents.

Mati Therapeutics

Company Details